Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Irinotecan Gastro-resistant Tablet. An Open Label Phase I, Dose Escalating Study Evaluating Safety, Tolerability and Pharmacokinetics of Oral Administration of Irinotecan in Adult Patients With Solid Tumors

Trial Profile

Irinotecan Gastro-resistant Tablet. An Open Label Phase I, Dose Escalating Study Evaluating Safety, Tolerability and Pharmacokinetics of Oral Administration of Irinotecan in Adult Patients With Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary) ; Irinotecan (Primary)
  • Indications Cervical cancer; Cholangiocarcinoma; Colon cancer; Mesothelioma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Rectal cancer; Small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 08 Apr 2019 According to an Ascelia Pharma media release, results from extension study were published in Cancer Chemotherapy and Pharmacology, a peer reviewed medical journal covering oncological pharmacotherapy.
    • 20 Feb 2019 Status changed from active, no longer recruiting to completed, according to an Ascelia Pharma media release.
    • 13 Nov 2018 According to an Ascelia Pharma media release, results from this trial have been newly published and are available on pubmed.gov titled "Oral administration of irinotecan in patients with solid tumours: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics".
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top